A Phase 3 interventional study of Ocrelizumab IV and Ocrelizumab SC in Relapsing Multiple Sclerosis and Primary Progressive Multiple Sclerosis, sponsored by Hoffmann-La Roche. Completed at 37 sites in 8 countries. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-08-11.
Sponsored by Hoffmann-La Roche · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 10 studies testing ocrelizumab in Multiple Sclerosis, Chronic Progressive — 2 open to participants now, 6 under way, 4 of them phase 3. ocrelizumab · Multiple Sclerosis, Chronic Progressive.
Among the 10 studies testing ocrelizumab in Multiple Sclerosis, Chronic Progressive, this one is the 5th largest by enrollment, is the only one that started in 2022, is one of 7 in phase 3, and was the 8th registered.
245 studies on the registry are indexed under Multiple Sclerosis, Chronic Progressive; 54 are open to participants now.
Browse Multiple Sclerosis, Chronic Progressive studies →2 of the 10 studies testing ocrelizumab in Multiple Sclerosis, Chronic Progressive are open now, in 3 countries. Recruiting first, the newest first:
Genentech, Inc. · Sites in United States, Puerto Rico
Ages 18–65
Assistance Publique - Hôpitaux de Paris · Sites in France
Ages 18–60 · Healthy volunteers
By country, each count listing its studies:
ocrelizumab: first FDA approval 2017 (OCREVUS), first EMA approval 2018. What it is approved for, and how studies give it, is on its page →
Of the 39 Multiple Sclerosis, Chronic Progressive studies recruiting now, 7 (18%) set no upper age limit and 26 (67%) stop at 75 or younger; none take children under 18; 6 take healthy volunteers.
This study: 18 Years to 65 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
10 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 2 1 · Phase 3 8 · Phase 4 2
First in 2011; this study’s year is marked. 1 started in 2022.
This study's enrollment of 236 is above the median of 54 across 190 interventional studies indexed under Multiple Sclerosis, Chronic Progressive.
Median enrollment 184 across the 10 interventional studies. Of the 4 that completed or were terminated, 4 (100%) have results posted.
This tab as a report to print or save as PDF → With an account.
8 of 10 have an industry lead sponsor. The 4 most frequent:
Hoffmann-La Roche is the lead sponsor of 2,102 studies on the registry; 89 are open to participants now.
Of its 331 completed or terminated interventional studies of FDA-regulated products, 248 (75%) have results posted.
12 studies in Multiple Sclerosis, Chronic Progressive by Hoffmann-La Roche: 2 open now, 8 under way, 4 of them phase 3. Of 4 finished, 4 (100%) have results posted.
Among the 12 studies in Multiple Sclerosis, Chronic Progressive by Hoffmann-La Roche, this one is the 8th largest by enrollment, is the only one that started in 2022, is one of 7 in phase 3, and was the 8th registered.
Hoffmann-La Roche’s Multiple Sclerosis, Chronic Progressive studies by the year they started, since 2004.
None of the studies under way reaches primary completion within a year.
Among the 10 studies testing ocrelizumab in Multiple Sclerosis, Chronic Progressive, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Hoffmann-La Roche’s 12 in Multiple Sclerosis, Chronic Progressive:
This tab as a report to print or save as PDF → With an account.
This study will evaluate the pharmacokinetics, pharmacodynamics, safety, immunogenicity, and radiological and clinical effects of subcutaneous (SC) administration of ocrelizumab compared with the intravenous (IV) infusion of ocrelizumab in patients with either relapsing multiple sclerosis (RMS) or primary progressive multiple sclerosis (PPMS).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.
Criteria about it usually ask for contraception during the study and for a time after it.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Reproductive potential
Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.
Criteria about it usually ask for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Live vaccines
Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Washout period
A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will receive the first dose of ocrelizumab IV as two IV infusions given 14 days apart. The subsequent doses of study drug will be administered as SC injections. A minimum of 22 weeks should be kept between SC doses. Participants will undergo 96 weeks of study treatment.
Drug: Ocrelizumab IV · Drug: Methylprednisolone IV · Drug: Diphenhydramine IV
Participants will receive the first dose of ocrelizumab SC as one SC injection at a dose which is expected to result in non-inferior exposure to ocrelizumab IV. The subsequent doses of study drug will be administered as SC injections. A minimum of 22 weeks should be kept between the first and second SC doses, and between subsequent SC doses. Participants will undergo 96 weeks of study treatment.
Drug: Ocrelizumab SC · Drug: Dexamethasone given orally · Drug: Desloratadine given orally
IV Injection
Also known as: RO4964913
SC Injection
Also known as: RO4964913
Participants will receive mandatory (corticosteroids and antihistamine) and optional (analgesic) prophylactic treatment before the start of each ocrelizumab infusion
Participants will receive mandatory (corticosteroids and antihistamine) and optional (analgesic) prophylactic treatment before the start of each ocrelizumab infusion
Participants will receive mandatory (corticosteroids and antihistamine) and optional (analgesic) prophylactic treatment before the start of each ocrelizumab injection
Participants will receive mandatory (corticosteroids and antihistamine) and optional (analgesic) prophylactic treatment before the start of each ocrelizumab injection
Serum Ocrelizumab Area Under the Concentration-Time Curve Over the First 12 Weeks (AUCW1-12) After SC Administration
Time frame: Day 1 Week 1 to Week 12
Maximum Serum Concentration (Cmax) of Ocrelizumab SC
Time frame: Day 1 Week 1 to Week 24
Rate of Gadolinium-enhancing Lesions on T1-weighted (T1Gd+) Lesions as Detected by Brain Magnetic Resonance Imaging (MRI) at Weeks 8 and 24
Radiologic evaluation for the total number of T1Gd+ lesions was performed using a standardized MRI at Weeks 8 and 24 to monitor central nervous system (CNS) lesions in participants with MS. Estimand variable (adjusted lesion rate) was modeled by a negative binomial regression that included treatment variable \& was adjusted for covariates: baseline T1Gd+ lesion (present or not), geographical region (United States of America vs. Rest of the world). EE = Efficacy-evaluable.
Time frame: At Weeks 8 and 24
Rate of New or Enlarging T2 Lesions as Detected by Brain MRI at Weeks 12 and 24
Radiologic evaluation for the new or enlarging T2 lesions was performed using a standardized MRI at Weeks 12 and 24 to monitor CNS lesions in participants with MS. Estimand variable (adjusted lesion rate) was modeled by a negative binomial regression that included treatment variable \& was adjusted for covariates: baseline T2 lesion count, geographical region (United States of America vs. Rest of the world).
Time frame: At Weeks 12 and 24
Number of Participants With Adverse Events (AEs)
An AE was any untoward medical occurrence in a clinical investigation participant administered a pharmaceutical product, regardless of causal attribution. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product.
Time frame: From initiation of study drug until 24 weeks after the final dose of study drug (up to 138.1 weeks)
Number of Participants With Anti-drug Antibodies (ADAs) to Ocrelizumab After SC or IV Administration
Participants who received ocrelizumab were considered to be treatment-emergent ADA-positive if they were ADA-negative or had missing data at baseline but developed an ADA response following ocrelizumab exposure (treatment-induced ADA response), or if they were ADA-positive at baseline and the titer of one or more post-baseline samples was at least 0.60 titer units (t.u.) greater than the titer of the baseline sample (treatment-enhanced ADA response). Participants with a positive post-baseline sample has been reported here.
Time frame: Up to 138.1 weeks
Number of Participants With ADAs to rHuPH20 After Ocrelizumab SC Administration
Ocrelizumab SC formulation is co-formulated with rHuPH20 at a concentration of 1000 units per milliliter (U/mL). Participants who received ocrelizumab SC were considered to be treatment-emergent ADA-positive if they were ADA-negative or had missing data at baseline but developed an ADA response following ocrelizumab SC exposure (treatment-induced ADA response), or if they were ADA-positive at baseline and the titer of one or more post-baseline samples was at least 0.60 titer units (t.u.) greater than the titer of the baseline sample (treatment-enhanced ADA response). Participants with a positive post-baseline sample has been reported here.
Time frame: Up to 138.1 weeks
Percentage of Participants Who Achieved CD19+ B Cell Level of ≤5 Cells/Microliters (µL) at Weeks 12, 24, 48, and/or 96
B-cells were assessed in fresh whole blood using flow cytometry. Percentages have been rounded off.
Time frame: At Weeks 12, 24, 48, and 96
A total of 236 participants with primary progressive multiple sclerosis (PPMS) or relapsing multiple sclerosis (RMS) took part in the study at 37 investigative sites across 8 countries from 03 May 2022 to 06 June 2025.
| Milestone | Ocrelizumab IV | Ocrelizumab SC |
|---|---|---|
| Started | 118 | 118 |
| Completed | 115 | 118 |
| Not completed | 3 | 0 |
| Withdrew: Discontinued and entered sfu period | 2 | 0 |
| Withdrew: Physician decision | 1 | 0 |
| Milestone | Ocrelizumab IV | Ocrelizumab SC |
|---|---|---|
| Started | 115 | 118 |
| Completed | 109 | 110 |
| Not completed | 6 | 8 |
| Withdrew: Discontinued and entered sfu period | 2 | 5 |
| Withdrew: Withdrawal by subject | 3 | 3 |
| Withdrew: Adverse event | 1 | 0 |
| Milestone | Ocrelizumab IV | Ocrelizumab SC |
|---|---|---|
| Started | 113 | 115 |
| Completed | 112 | 115 |
| Not completed | 1 | 0 |
| Withdrew: Lost to follow-up | 1 | 0 |
| micrograms/milliliters*day (µg/mL*day) | Ocrelizumab IV | Ocrelizumab SC |
|---|---|---|
| Serum Ocrelizumab Area Under the Concentration-Time Curve Over the First 12 Weeks (AUCW1-12) After SC Administration | 2750 ± 796 | 3500 ± 914 |
| micrograms/milliliters (µg/mL) | Ocrelizumab IV | Ocrelizumab SC |
|---|---|---|
| Maximum Serum Concentration (Cmax) of Ocrelizumab SC | 137 ± 29.5 | 132 ± 31.9 |
Radiologic evaluation for the total number of T1Gd+ lesions was performed using a standardized MRI at Weeks 8 and 24 to monitor central nervous system (CNS) lesions in participants with MS. Estimand variable (adjusted lesion rate) was modeled by a negative binomial regression that included treatment variable \& was adjusted for covariates: baseline T1Gd+ lesion (present or not), geographical region (United States of America vs. Rest of the world). EE = Efficacy-evaluable.
| lesions per participant | Ocrelizumab IV | Ocrelizumab SC |
|---|---|---|
| At Week 8 | 0.060 (0.020 to 0.150) | 0.060 (0.020 to 0.140) |
| At Week 24 | 0.000 (0.000 to NA) | 0.000 (0.000 to NA) |
Radiologic evaluation for the new or enlarging T2 lesions was performed using a standardized MRI at Weeks 12 and 24 to monitor CNS lesions in participants with MS. Estimand variable (adjusted lesion rate) was modeled by a negative binomial regression that included treatment variable \& was adjusted for covariates: baseline T2 lesion count, geographical region (United States of America vs. Rest of the world).
| lesions per participant | Ocrelizumab IV | Ocrelizumab SC |
|---|---|---|
| At Week 12 | 0.050 (0.010 to 0.170) | 0.020 (0.000 to 0.100) |
| At Week 24 | 0.000 (0.000 to 0.000) | 0.000 (0.000 to 0.010) |
An AE was any untoward medical occurrence in a clinical investigation participant administered a pharmaceutical product, regardless of causal attribution. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product.
| Participants | Ocrelizumab IV | Ocrelizumab SC |
|---|---|---|
| Number of Participants With Adverse Events (AEs) | 101 | 111 |
Participants who received ocrelizumab were considered to be treatment-emergent ADA-positive if they were ADA-negative or had missing data at baseline but developed an ADA response following ocrelizumab exposure (treatment-induced ADA response), or if they were ADA-positive at baseline and the titer of one or more post-baseline samples was at least 0.60 titer units (t.u.) greater than the titer of the baseline sample (treatment-enhanced ADA response). Participants with a positive post-baseline sample has been reported here.
| Participants | Ocrelizumab IV | Ocrelizumab SC |
|---|---|---|
| Number of Participants With Anti-drug Antibodies (ADAs) to Ocrelizumab After SC or IV Administration | 0 | 0 |
Ocrelizumab SC formulation is co-formulated with rHuPH20 at a concentration of 1000 units per milliliter (U/mL). Participants who received ocrelizumab SC were considered to be treatment-emergent ADA-positive if they were ADA-negative or had missing data at baseline but developed an ADA response following ocrelizumab SC exposure (treatment-induced ADA response), or if they were ADA-positive at baseline and the titer of one or more post-baseline samples was at least 0.60 titer units (t.u.) greater than the titer of the baseline sample (treatment-enhanced ADA response). Participants with a positive post-baseline sample has been reported here.
| Participants | Ocrelizumab IV | Ocrelizumab SC |
|---|---|---|
| Number of Participants With ADAs to rHuPH20 After Ocrelizumab SC Administration | 1 | 4 |
B-cells were assessed in fresh whole blood using flow cytometry. Percentages have been rounded off.
| percentage of participants | Ocrelizumab IV | Ocrelizumab SC |
|---|---|---|
| At Week 12 | 98.3 | 98.3 |
| At Week 24 | 78.9 | 74.6 |
| At Week 48 | 92.0 | 86.0 |
| At Week 96 | 92.5 | 90.7 |
Collected over From initiation of study drug until 24 weeks after the final dose of study drug (up to 138.1 weeks). Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Ocrelizumab IV | 0/118 (0%) | 9/118 (7.6%) | 86/118 (72.9%) |
| Ocrelizumab SC | 0/118 (0%) | 7/118 (5.9%) | 99/118 (83.9%) |
| Event | Ocrelizumab IV | Ocrelizumab SC |
|---|---|---|
| Multiple sclerosis pseudo relapseNervous system disorders | 0/118 | 2/118 |
| Eye painEye disorders | 0/118 | 1/118 |
| AppendicitisInfections and infestations | 1/118 | 0/118 |
| Cellulitis staphylococcalInfections and infestations | 1/118 | 0/118 |
| PneumoniaInfections and infestations | 1/118 | 0/118 |
| Subcutaneous abscessInfections and infestations | 1/118 | 0/118 |
| Upper respiratory tract infectionInfections and infestations | 1/118 | 0/118 |
| Diabetes mellitusMetabolism and nutrition disorders | 1/118 | 0/118 |
| Multiple sclerosis relapseNervous system disorders | 0/118 | 1/118 |
| AnxietyPsychiatric disorders | 0/118 | 1/118 |
| Event | Ocrelizumab IV | Ocrelizumab SC |
|---|---|---|
| Injection related reactionInjury, poisoning and procedural complications | 55/118 | 74/118 |
| Infusion related reactionInjury, poisoning and procedural complications | 20/118 | 0/118 |
| COVID-19Infections and infestations | 12/118 | 19/118 |
| Upper respiratory tract infectionInfections and infestations | 18/118 | 18/118 |
| Urinary tract infectionInfections and infestations | 12/118 | 15/118 |
| HeadacheNervous system disorders | 6/118 | 13/118 |
| NasopharyngitisInfections and infestations | 6/118 | 11/118 |
| BronchitisInfections and infestations | 9/118 | 10/118 |
| RhinitisInfections and infestations | 1/118 | 10/118 |
| Oral herpesInfections and infestations | 1/118 | 7/118 |
Safety evaluable (SE) - all set included all randomized participants who received at least one infusion (partial or complete) or injection (partial or complete) of study drug, grouped according to treatment received at first exposure.
| Age, Continuous(years) | Ocrelizumab IV | Ocrelizumab SC | Total |
|---|---|---|---|
| Mean | 40.0 ± 11.9 | 39.9 ± 11.4 | 39.9 ± 11.6 |
| Sex: Female, Male(Participants) | Ocrelizumab IV | Ocrelizumab SC | Total |
|---|---|---|---|
| Female | 70 | 77 | 147 |
| Male | 48 | 41 | 89 |
| Ethnicity (NIH/OMB)(Participants) | Ocrelizumab IV | Ocrelizumab SC | Total |
|---|---|---|---|
| Hispanic or Latino | 8 | 8 | 16 |
| Not Hispanic or Latino | 93 | 94 | 187 |
| Unknown or Not Reported | 17 | 16 | 33 |
| Race (NIH/OMB)(Participants) | Ocrelizumab IV | Ocrelizumab SC | Total |
|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 |
| Asian | 1 | 0 | 1 |
| Native Hawaiian or Other Pacific Islander | 1 | 0 | 1 |
| Black or African American | 1 | 7 | 8 |
| White | 109 | 102 | 211 |
| More than one race | 1 | 3 | 4 |
| Unknown or Not Reported | 5 | 6 | 11 |
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from May 2022 to primary completion in Mar 2023, 10 months.
Results were first posted in Aug 2026, 3 years 5 months after primary completion.
Of 20 phase 3 interventional studies under Multiple Sclerosis, Chronic Progressive, half reached primary completion within 61 months of starting (the median), counting those still running; a quarter within 52 and three quarters within 83. This study's 10 months is below that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jul 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Ocrelizumab
Multiple Sclerosis, Chronic Progressive →